SCM
VIRX

Stonepine Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Stonepine Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500,000
Closed -$116K – 58
2024
Q3 		$116K Buy
+500,000
New +$183K 0.07% 37

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stonepine Capital Management's VIRX Position: Q4 2024 in Review

Stonepine Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2024, closing a stake of 500,000 shares — an estimated $116K sold.

Stonepine Capital Management first reported a position in VIRX in Q3 2024 and held it in 1 quarter. The position peaked at $116K in Q3 2024. 32 funds tracked by Wall St. Rank hold VIRX as of Q4 2024.

  • Stonepine Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Stonepine Capital Management sold 500,000 Viracta Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $116K.
  • Stonepine Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2024 and held it in 1 quarter.
  • Stonepine Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $116K in Q3 2024.
  • 32 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Stonepine Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.